Madrigal Pharmaceuticals Inc (MDGL NASDAQ) stock market data APIs
$434.1199
20.43(4.7%)
as of February 19, 2026
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
434.1199
Open
454.5473
High
460.8288
Low
424.6535
52 wk Range
265-615
Market Cap
11 162 M
Shares Outstanding
22 711 K
Revenue
741 M
EPS
0
Beta
-1.019
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Madrigal Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
ILDR.US
First Trust Exchange-Traded Fund VIII - First Trust Innovation Leaders ETF
-2.19
(-6.5%)
1.37
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 741 M
- EBITDA: -306 007 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-19
- EPS/Forecast: -0.6039
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
John Paulson's Strategic Moves: Madrigal Pharmaceuticals Inc. Sees a -3.09% Impact
This article first appeared on GuruFocus. Insights into John Paulson (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Warning! GuruFocus has detected 5 Warning Signs with MDGL. Is MDGL fairly va...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals(NASDAQ:AGIO) in the fourth quarter, an estimated $5.59 million ...
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
On February 17, 2026, Rock Springs Capital Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 159,278 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $...
Get Madrigal Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
